Vaccination strategies in patients with IBD

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 5, 2013, Pages 277-285

  Gisbert, Javier P ^a   Chaparro, María ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BCG VACCINE; CHICKENPOX VACCINE; CORTICOSTEROID; DIPHTHERIA VACCINE; ENERGIX B; HEPATITIS ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MERCAPTOPURINE; METHOTREXATE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PREDNISONE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; TUMOR NECROSIS FACTOR ANTIBODY; TYPHOID VACCINE; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTIBODY TITER; BACTERIAL TRANSMISSION; CHILD HEALTH CARE; DIPHTHERIA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; MEASLES; MUMPS; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; RELAPSE; REVACCINATION; REVIEW; RUBELLA; SEROCONVERSION; SEROLOGY; TETANUS; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VACCINATION; VIRUS TRANSMISSION; WART VIRUS;

HUMANS; IMMUNIZATION SCHEDULE; IMMUNOSUPPRESSIVE AGENTS; INFECTION; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES AS TOPIC; VACCINATION; VACCINES;

EID: 84877586211     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.28     Document Type: Review

References (99)

1. Viget, N., Vernier-Massouille, G., Salmon-Ceron, D., Yazdanpanah, Y. & Colombel, J. F. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 57, 549-558 (2008).
2. Rahier, J. F. et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis 3, 47-91 (2009).
3. Rahier, J. F. et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 49, 1815-1827 (2010).
4. Sands, B. E. et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 10, 677-692 (2004).
5. Demicheli, V., Jefferson, T., Rivetti, A. & Price, D. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD004407. http://dx.doi.org/10.1002/14651858.CD004407.pub2.
6. Chalmers, A. et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J. Rheumatol. 21, 1203-1206 (1994).
7. Centers for Disease Control. Guide to Vaccine Contraindications and Precautions. CDC [online], http://www.cdc.gov/vaccines/recs/vac-admin/downloads/ contraindications-guide-508.pdf (2009).
8. Levin, M. J. Varicella vaccination of immunocompromised children. J. Infect. Dis. 197 (Suppl. 2), S200-S206 (2008).
9. Lu, Y. & Bousvaros, A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J. Pediatr. Gastroenterol. Nutr. 50, 562-565 (2010).
10. Coates, T., Wilson, R., Patrick, G., Andre, F. & Watson, V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin. Ther. 23, 392-403 (2001).
11. Mast, E. E. et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm. Rep. 55, 1-33 (2006).
12. WHO Publication. Hepatitis B vaccines: WHO position paper -recommendations. Vaccine 28, 589-590 (2009).
13. Hou, J. K., Velayos, F., Terrault, N. & Mahadevan, U. Viral hepatitis and inflammatory bowel disease. Inflamm. Bowel Dis. 16, 925-932 (2010).
14. Gisbert, J. P., Chaparro, M. & Esteve, M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 33, 619-633 (2011).
15. Moses, J. et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am. J. Gastroenterol. 107, 133-138 (2012).
16. Melmed, G. Y. et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am. J. Gastroenterol. 101, 1834-1840 (2006).
17. Melmed, G. Y. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm. Bowel Dis. 15, 1410-1416 (2009).
18. Wasan, S. K., Baker, S. E., Skolnik, P. R. & Farraye, F. A. A practical guide to vaccinating the inflammatory bowel disease patient. Am. J. Gastroenterol. 105, 1231-1238 (2010).
19. Vida Pérez, L. et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease [Spanish]. Med. Clin. (Barc.) 132, 331-335 (2009).
20. Altunoz, M. E., Senates, E., Yesil, A., Calhan, T. & Ovunc, A. O. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig. Dis. Sci. 57, 1039-1044 (2012).
21. Gisbert, J. P., Villagrasa, J. R., Rodriguez-Nogueiras, A. & Chaparro, M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am. J. Gastroenterol. 107, 1460-1466 (2012).
22. [No authors listed] Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 355, 561-565 (2000).
23. Brezinschek, H. P., Hofstaetter, T., Leeb, B. F., Haindl, P. & Graninger, W. B. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr. Opin. Rheumatol. 20, 295-299 (2008).
24. Shouval, D. Hepatitis B vaccines. J. Hepatol. 39 (Suppl. 1), S70-S76 (2003).
25. Zuin, G. et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 10, 857-860 (1992).
26. Scolfaro, C., Fiammengo, P., Balbo, L., Madon, E. & Tovo, P. A. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS 10, 1169-1170 (1996).
27. Bruguera, M. et al. Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am. J. Med. 87, 30S-32S (1989).
28. Choudhury, S. A. & Peters, V. B. Responses to hepatitis B vaccine boosters in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 14, 65-67 (1995).
29. Fonseca, M. O., Pang, L. W., de Paula Cavalheiro, N., Barone, A. A. & Heloisa Lopes, M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 23, 2902-2908 (2005).
30. Rey, D. et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 18, 1161-1165 (2000).
31. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2010. Ann. Intern. Med. 152, 36-39 (2010).
32. Gisbert, J. P. et al. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 35, 1379-1385 (2012).
33. Lok, A. S. & McMahon, B. J. Chronic hepatitis B. Hepatology 45, 507-539 (2007).
34. Jack, A. D., Hall, A. J., Maine, N., Mendy, M. & Whittle, H. C. What level of hepatitis B antibody is protective? J. Infect. Dis. 179, 489-492 (1999).
35. John, T. J. & Cooksley, G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations? J. Gastroenterol. Hepatol. 20, 5-10 (2005).
36. Chen, D. S. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J. Hepatol. 50, 805-816 (2009).
37. Chevaux, J. B. et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm. Bowel Dis. 16, 916-924 (2010).
38. Gisbert, J. P., Villagrasa, J. R., Rodríguez-Nogueiras, A. & Chaparro, M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm. Bowel Dis. http://dx.doi.org/10.1097/MIB.0b013e31827febe9
39. Floreani, A. et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 22, 607-610 (2004).
40. Sezer, S. et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant. Proc. 32, 607-608 (2000).
41. Navarro, J. F., Teruel, J. L., Mateos, M. L., Marcen, R. & Ortuno, J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am. J. Nephrol. 16, 95-97 (1996).
42. Zuckerman, J. N., Sabin, C., Craig, F. M., Williams, A. & Zuckerman, A. J. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 314, 329-333 (1997).
43. Goldwater, P. N. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 15, 353-356 (1997).
44. Cardell, K., Akerlind, B., Sallberg, M. & Fryden, A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J. Infect. Dis. 198, 299-304 (2008).
45. Tan, K. L., Goh, K. T., Oon, C. J. & Chan, S. H. Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization. JAMA 271, 859-861 (1994).
46. Clemens, R. et al. Booster immunization of low-and non-responders after a standard three dose hepatitis B vaccine schedule -results of a post-marketing surveillance. Vaccine 15, 349-352 (1997).
47. Craven, D. E. et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann. Intern. Med. 105, 356-360 (1986).
48. Kim, M. J. et al. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 21, 1174-1179 (2003).
49. Weissman, J. Y. et al. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 260, 1734-1738 (1988).
50. Hadler, S. C. et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 315, 209-214 (1986).
51. Nye, F. J. & Kennedy, N. Update on vaccination guidelines. Br. J. Hosp. Med. 57, 313-318 (1997).
52. Bertino, J. S. Jr et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J. Infect. Dis. 175, 678-681 (1997).
53. Lu, Y., Jacobson, D. & Bousvaros, A. Immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15, 1417-1423 (2009).
54. Hall, A. J. Boosters for hepatitis B vaccination? Need for an evidence-based policy. Hepatology 51, 1485-1486 (2010).
55. West, D. J. & Calandra, G. B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14, 1019-1027 (1996).
56. Stevens, C. E. et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N. Engl. J. Med. 311, 496-501 (1984).
57. Palefsky, J. Human papilloma virus infection in HIV-infected persons. Top. HIV Med. 15, 130-133 (2007).
58. Munoz, C. Human papillomavirus and cancer: the epidemiological evidence. J. Clin. Virol. 19, 1-5 (2000).
59. Munoz, N. et al. Epidemiology classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348, 518-527 (2003).
60. Sinclair, J. A., Wasan, S. K. & Farraye, F. A. Health maintenance in the inflammatory bowel disease patient. Gastroenterol. Clin. N. Am. 41, 325-337 (2012).
61. Harper, D. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
62. Villa, L. L. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6, 271-278 (2005).
63. Arbyn, M. & Dillner, J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J. Clin. Virol. 38, 189-197 (2007).
64. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009. Ann. Intern. Med. 150, 40-44 (2009).
65. deBruyn, J. C. et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm. Bowel Dis. 18, 25-33 (2012).
66. Schanzer, D. L., Langley, J. M. & Tam, T. W. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respi. Viruses 2, 1-8 (2008).
67. Schanzer, D. L., Langley, J. M. & Tam, T. W. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr. Infect. Dis. J. 25, 795-800 (2006).
68. Billings, J. L., Hertz, M. I., Savik, K. & Wendt, C. H. Respiratory viruses and chronic rejection in lung transplant recipients. J. Heart. Lung Transplant. 21, 559-566 (2002).
69. Hassan, I. A., Chopra, R., Swindell, R. & Mutton, K. J. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant. 32, 73-77 (2003).
70. Fiore, A. E. et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm. Rep. 56, 1-54 (2007).
71. Lu, Y. et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am. J. Gastroenterol. 104, 444-453 (2009).
72. Mamula, P. et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5, 851-856 (2007).
73. Cullen, G., Bader, C., Korzenik, J. R. & Sands, B. E. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 61, 385-391 (2012).
74. Targonski, P. V. & Poland, G. A. Pneumococcal vaccination in adults: recommendations, trends, and prospects. Cleve. Clin. J. Med. 74, 401-406, 408-410, 413-414 (2007).
75. Melmed, G. Y. et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105, 148-154 (2010).
76. Dotan, I. et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm. Bowel Dis. 18, 261-268 (2012).
77. Brogan, M. D., Shanahan, F., Oliver, M., Stevens, R. H. & Targan, S. R. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J. Clin. Lab. Immunol. 24, 69-74 (1987).
78. Nielsen, H. J. et al. Increased levels of specific leukocyte-and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand. J. Gastroenterol. 36, 265-269 (2001).
79. Bernstein, C. N., Rawsthorne, P. & Blanchard, J. F. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm. Bowel Dis. 13, 759-762 (2007).
80. [No authors listed] Prevention of varicella: recommendations of the Advisory Committee of Immunization Practice (ACIP). Centers for Disease Control and Prevention. MMWR Recomm. Rep. 45, 1-36 (1996).
81. Marin, M., Guris, D. & Chaves, S. S. Prevention of varicella: recommendation of the Advisory Committee on Immunization Practice (ACIP). MMWR Recomm. Rep. 56, 1-40 (2007).
82. Gupta, G., Lautenbach, E. & Lewis, J. D. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4, 1483-1490 (2006).
83. Moscandrew, M., Mahadevan, U. & Kane, S. General health maintenance in IBD. Inflamm. Bowel Dis. 15, 1399-1409 (2009).
84. Harpaz, R., Ortega-Sánchez, I. R. & Seward, J. F. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 57, 1-30 (2008).
85. Kotton, C. N. Nailing down the shingles in IBD. Inflamm. Bowel Dis. 13, 1178-1179 (2007).
86. Singh, A. & Englund, K. Q: Who should receive the shingles vaccine? Cleve. Clin. J. Med. 76, 45-48 (2009).
87. Zhang, J. et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 308, 43-49 (2012).
88. Chaparro, M. & Gisbert, J. P. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr. Pharm. Biotechnol. 12, 765-773 (2011).
89. Dubinsky, M., Abraham, B. & Mahadevan, U. Management of the pregnant IBD patient. Inflamm. Bowel Dis. 14, 1736-1750 (2008).
90. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years -United States, 2009. MMWR 57 (2008).
91. Anderson, E. J. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect. Dis. 8, 642-649 (2008).
92. Kroger, A. T., Atkinson, W. L., Marcuse, E. K. & Pickering, L. K. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55, 1-48 (2006).
93. Parashar, U. D., Alexander, J. P. & Glass, R. I. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55, 1-13 (2006).
94. Yeung, J. H., Goodman, K. J. & Fedorak, R. N. Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm. Bowel Dis. 18, 34-40 (2012).
95. Melmed, G. Y. Immunizations and IBD: whose responsibility is it? If I'm the prescribing doctor, shouldn't it be mine? Inflamm. Bowel Dis. 18, 41-42 (2012).
96. Wilckens, V. et al. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand. J. Gastroenterol. 46, 855-861 (2011).
97. Wasan, S. K., Coukos, J. A. & Farraye, F. A. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm. Bowel Dis. 17, 2536-2540 (2011).
98. Gupta, A., Macrae, F. A. & Gibson, P. R. Vaccination and screening for infections in patients with inflammatory bowel disease: a survey of Australian gastroenterologists. Intern. Med. J. 41, 462-467 (2011).
99. Loras, C. et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am. J. Gastroenterol. 104, 57-63 (2009).